Literature DB >> 6692258

The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases.

J Costa, R A Wesley, E Glatstein, S A Rosenberg.   

Abstract

A multidisciplinary study of 163 patients treated at the NCI for soft tissue sarcomas allowed the correlation of a number of histologic features (histologic type, mitosis, necrosis, pleomorphism, cellularity, and matrix) of the primary lesion to time to recurrence and overall survival of the patients. The results of the stratified analyses show that necrosis is the single best histopathologic parameter to predict the time to recurrence (P = 0.025) and the overall survival of the patients (P = 0.002). Necrosis in the primary lesion is also of value in predicting survival after the first recurrence has taken place (P = 0.001). The value of necrosis in the primary lesions predicting the clinical course after recurrence appears to be independent of age, sex, location, and size of the tumor. The authors propose a grading system based on histologic typing and histologic parameters to identify a group of lesions with minimal metastatic potential (Grade 1), and on the use of necrosis to distinguish between aggressive lesions with good patient survival (Grade 2) and aggressive lesions with poor patient survival (Grade 3).

Entities:  

Mesh:

Year:  1984        PMID: 6692258     DOI: 10.1002/1097-0142(19840201)53:3<530::aid-cncr2820530327>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  60 in total

1.  Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.

Authors:  Christian Hagel; Ulrich Zils; Matthias Peiper; Lan Kluwe; Stefan Gotthard; Reinhard E Friedrich; David Zurakowski; Andreas von Deimling; Victor Felix Mautner
Journal:  J Neurooncol       Date:  2006-11-17       Impact factor: 4.130

2.  Soft tissue sarcoma with metastasis to the stomach: a case report.

Authors:  Lemuel Leon Dent; Cesar Yamil Cardona; Michael Clause Buchholz; Roosevelt Peebles; Julie Denise Scott; Derrick Jerome Beech; Billy Ray Ballard
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

Review 3.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

4.  Primary myxoid sarcoma of the pleura.

Authors:  Walid Abu Arab; Vincent Echavé; Marco Sirois; Francois Bénard; Marcio M Gomes
Journal:  Can J Surg       Date:  2009-08       Impact factor: 2.089

5.  Alveolar rhabdomyosarcoma in a young female patient metastasizing to the brain.

Authors:  R Kleinert; A Beham; G Rosanelli
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

Review 6.  A guide to oncological management of soft tissue tumours of the abdominal wall.

Authors:  K J Williams; A J Hayes
Journal:  Hernia       Date:  2013-09-17       Impact factor: 4.739

7.  Prognostic value of histological grading in ductal adenocarcinoma of the pancreas. Klöppel vs TNM grading.

Authors:  P C Giulianotti; U Boggi; G Fornaciari; J Bruno; G Rossi; D Giardino; G Di Candio; F Mosca
Journal:  Int J Pancreatol       Date:  1995-06

8.  Malignant transformation of human fibroblast cell strain MSU-1.1 by (+-)-7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-epoxy-7,8,9,10-tetrahydrobenzo [a]pyrene.

Authors:  D Yang; C Louden; D S Reinhold; S K Kohler; V M Maher; J J McCormick
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

9.  Sarcoma of the breast. A study of 32 patients with reappraisal of classification and therapy.

Authors:  C D Callery; P P Rosen; D W Kinne
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

10.  Prognostic significance of spontaneous tumour necrosis in osteosarcoma.

Authors:  J Björnsson; C Y Inwards; L E Wold; F H Sim; W F Taylor
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.